164 related articles for article (PubMed ID: 35971313)
1. Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations.
Chung C; Yeung VTY; Wong KCW
J Oncol Pharm Pract; 2023 Sep; 29(6):1343-1360. PubMed ID: 35971313
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
3. Update on prognostic and predictive biomarkers of breast cancer.
Hou Y; Peng Y; Li Z
Semin Diagn Pathol; 2022 Sep; 39(5):322-332. PubMed ID: 35752515
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancer: promising prognostic biomarkers currently in development.
Sukumar J; Gast K; Quiroga D; Lustberg M; Williams N
Expert Rev Anticancer Ther; 2021 Feb; 21(2):135-148. PubMed ID: 33198517
[No Abstract] [Full Text] [Related]
5. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation.
Chung C
J Oncol Pharm Pract; 2022 Jun; 28(4):850-869. PubMed ID: 33832365
[TBL] [Abstract][Full Text] [Related]
6. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
7. Updates on breast biomarkers.
Najjar S; Allison KH
Virchows Arch; 2022 Jan; 480(1):163-176. PubMed ID: 35029776
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.
Chung C; Christianson M
J Oncol Pharm Pract; 2014 Feb; 20(1):11-28. PubMed ID: 23493335
[TBL] [Abstract][Full Text] [Related]
9. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
[TBL] [Abstract][Full Text] [Related]
10. A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.
Jagannathan G; White MJ; Xian RR; Emens LA; Cimino-Mathews A
Clin Lab Med; 2023 Jun; 43(2):299-321. PubMed ID: 37169447
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
Nicolini A; Ferrari P; Duffy MJ
Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
[TBL] [Abstract][Full Text] [Related]
13. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
Colomer R; González-Farré B; Ballesteros AI; Peg V; Bermejo B; Pérez-Mies B; de la Cruz S; Rojo F; Pernas S; Palacios J
Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38869741
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation.
Chung C; Umoru G
J Oncol Pharm Pract; 2024 Apr; ():10781552241242684. PubMed ID: 38576390
[TBL] [Abstract][Full Text] [Related]
16. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Wen WX; Leong CO
PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
[TBL] [Abstract][Full Text] [Related]
17. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
18. Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer.
Freelander A; Brown LJ; Parker A; Segara D; Portman N; Lau B; Lim E
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33671468
[TBL] [Abstract][Full Text] [Related]
19. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
20. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]